Nuvalent Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$10.7Mnext fiscal year
FY EPS (est.)
-$5.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Neladalkib PDUFA Target Action Date | 27 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly1.3BTarget: Fund operations into 2029
Quarterly Net Loss Quarterly-109.3MTarget: N/A (Clinical-stage cash burn)
Watch Items
- GSK Acquisition ClosingTrigger: $124.00 per share all-cash transactionAction: Monitor regulatory approvals and shareholder votes ahead of expected Q3 2026 close
- Zidesamtinib FDA PDUFA DateTrigger: September 18, 2026Action: Track FDA decision on NDA for ROS1-positive NSCLC
- Neladalkib FDA PDUFA DateTrigger: November 27, 2026Action: Track FDA decision on NDA for ALK-positive NSCLC under Priority Review
Research as of 2 Sep 2026